Should I buy or sell Accolade stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks .

What is Accolade's stock price target for 2024?

16 Wall Street research analysts have issued 1 year price targets for Accolade's stock. Their ACCD share price targets range from $10.00 to $19.00. On average, they anticipate the company's share price to reach $14.57 in the next year. This suggests a possible upside of 98.0% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts .

How have ACCD shares performed in 2024?

Accolade's stock was trading at $12.01 at the beginning of the year. Since then, ACCD shares have decreased by 38.7% and is now trading at $7.36. View the best growth stocks for 2024 here .

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ACCD earnings forecast .

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) released its earnings results on Thursday, April, 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $124.80 million for the quarter, compared to the consensus estimate of $123.91 million. Accolade had a negative trailing twelve-month return on equity of 22.53% and a negative net margin of 24.09%. The company's revenue was up 26.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.42) earnings per share.

What ETFs hold Accolade's stock?

ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , SPDR S&P Health Care Services ETF (XHS) , Fidelity Digital Health ETF (FDHT) , Global X Millennial Consumer ETF (MILN) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) . iShares U.S. Healthcare Providers ETF (IHF) .

What guidance has Accolade issued on next quarter's earnings?

Accolade issued an update on its first quarter 2025 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $103.0 million-$106.0 million, compared to the consensus revenue estimate of $110.9 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com . Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS) , Johnson & Johnson (JNJ) , RTX (RTX) , Alibaba Group (BABA) , Home Depot (HD) , Procter & Gamble (PG) , Thermo Fisher Scientific (TMO) , Cisco Systems (CSCO) and Intel (INTC) .

When did Accolade IPO?

Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.19%), Fairman Group LLC (1.47%), Los Angeles Capital Management LLC (0.07%), Mirae Asset Global Investments Co. Ltd. (0.04%), Principal Financial Group Inc. (0.03%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes. View institutional ownership trends .

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACCD

Accolade (ACCD) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free ACCD Stock Alerts

$7.36

-0.27 (-3.54%)

(As of 05/1/2024 ET)

Compare

Today's Range: $7.34
▼
$7.72
50-Day Range: $7.63
▼
$11.50
52-Week Range: $6.33
▼
$15.36

Volume: 1.01 million shs
Average Volume: 744,290 shs
Market Capitalization: $576.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.57

Get Accolade alerts:

Accolade MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 98.0% Upside
$14.57 Price Target
Short Interest: Healthy
4.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: 0.04
Based on 32 Articles This Week
Insider Trading: Selling Shares
$73,872 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.15) to ($0.99) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Business Services Sector

25th out of 310 stocks

Business Services, Not Elsewhere Classified Industry

9th out of 88 stocks

4.4

Analyst's Opinion

Consensus Rating
Accolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Accolade has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.01% of the outstanding shares of Accolade have been sold short.
Short Interest Ratio / Days to Cover
Accolade has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Accolade has recently decreased by 2.18%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Accolade does not currently pay a dividend.
Dividend Growth
Accolade does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.
Environmental Sustainability
The Environmental Impact score for Accolade is -0.89.

2.2

News and Social Media Coverage

News Sentiment
Accolade has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Business Services companies.
News Coverage This Week
MarketBeat has tracked 32 news articles for Accolade this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for ACCD on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,872.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Accolade is held by insiders.
Percentage Held by Institutions
84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accolade are expected to grow in the coming year, from ($1.15) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accolade is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accolade is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Accolade has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Banyan Hill Publishing

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

About Accolade Stock (NASDAQ:ACCD)

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACCD Stock News Headlines

May 1, 2024 | americanbankingnews.com

Accolade (NASDAQ:ACCD) Price Target Cut to $10.00 by Analysts at Wells Fargo & Company

April 30, 2024 | finance.yahoo.com

Accolade, Inc. (NASDAQ:ACCD) Q4 2024 Earnings Call Transcript

May 1, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

April 29, 2024 | americanbankingnews.com

Research Analysts Offer Predictions for Accolade, Inc.'s FY2026 Earnings (NASDAQ:ACCD)